ClinicalTrials.gg
RecruitingNCT07036978Updated Nov 19, 2026

Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer

An observational study in Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Chang Gung Memorial Hospital · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 19, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
140
Ages
18 Years and older
Sex
All
01

Study summary

Brief Summary

The goal of this observational study is to identify biomarkers and develop a personalised treatment stratification model for patients with unresectable pancreatic ductal adenocarcinoma (PDAC) in Taiwan. The main questions it aims to answer are:

  • What serum metabolomic profiles predict treatment response and patient survival?
  • How do immune response markers and gut microbiome composition correlate with therapeutic outcomes?
  • Can a combined multi-omic stratification algorithm enhance personalised therapy planning?

Participants, who have been diagnosed with unresectable locally advanced or metastatic PDAC and are undergoing systemic therapy and chemoradiotherapy, will:

  • Provide serum samples for comprehensive metabolomic profiling via high-performance liquid chromatography-mass spectrometry.
  • Undergo immune profiling through flow cytometry.
  • Provide stool samples for gut microbiome analysis using 16S rRNA sequencing.
  • Be followed longitudinally to correlate these multi-omic findings with clinical outcomes.

Researchers anticipate that integrating these multi-omic analyses will facilitate personalised therapy approaches, potentially improving patient outcomes.

Read the detailed description

Detailed Description \<Pancreatic cancer and current treatment landscape> Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterised by nearly equal incidence and mortality rates. Globally, in 2022, there were 511,000 new cases and 467,000 deaths, making PDAC the sixth leading cause of cancer mortality among both sexes combined. In Taiwan, pancreatic cancer ranks as the seventh leading cause of cancer death, accounting for 2,769 deaths in 2022. Over 80% of patients are diagnosed at an unresectable stage (locally advanced or metastatic), for which five-year survival is below 5%. Current systemic treatments such as FOLFIRINOX or gemcitabine-based chemotherapy provide only modest improvements in median survival, and most advanced PDAC ultimately develop therapeutic resistance. No effective stratification exists to guide individualised therapy in unresectable cases - all patients typically receive similar empiric regimens despite substantial biological heterogeneity.

\<Preliminary Data on Dose Escalation in Radiotherapy> Between 2015 and 2022, 231 patients with pancreatic cancer underwent locoregional radiotherapy at Linkou Chang Gung Memorial Hospital (CGMH). After applying exclusion criteria (e.g., prior surgery, small cell or neuroendocrine histology, insufficient radiotherapy dose, and inadequate follow-up), 145 patients were included in a retrospective analysis. Kaplan-Meier estimates indicated that patients receiving proton beam therapy (PBT)-either alone or in combination with X-ray radiotherapy (XRT)-demonstrated significantly better local control (LC) than those treated with XRT alone. In multivariate analysis, PBT was associated with a hazard ratio of 0.52 (95% CI 0.28-0.97; p = 0.039) for improved LC, underscoring the potential efficacy of proton-based modalities in unresectable PDAC.

Additionally, dose escalation correlated strongly with improved local outcomes. Patients prescribed ≥5940 cGy showed significantly higher one- and two-year local control (LC) rates of 100% and 88.4%, respectively, as well as an extended median LC of 28.1 months, compared to those receiving 4500-5940 cGy, which had one- and two-year LC rates of 73.3% and 40.8%, respectively, and a median LC of 18.1 months. These data highlight a dose-response relationship in locally advanced PDAC. While higher-dose PBT seems beneficial, intensifying the dose may increase toxicity and may not be suitable for all patients. Importantly, no established biomarker exists to identify those most likely to benefit from dose escalation.

\<Research Gap in Unresectable PDAC> The only widely used biomarker in PDAC is serum CA19-9, which has moderate prognostic and diagnostic value but has significant limitations. CA19-9 is false-negative in 5-10% of individuals who are Lewis-antigen negative and cannot produce the antigen. It also has poor specificity, being elevated in benign biliary obstruction and other conditions. Thus, patients (especially those without Lewis antigen expression or with jaundice) cannot rely on CA19-9 for stratification. In the absence of any robust alternative biomarker to predict which unresectable PDAC patients will benefit from intensive treatment versus those who might avoid futile toxicity, the critical research gap is to identify new biomarkers that can classify advanced PDAC patients into subgroups predictive of treatment response or prognosis. This gap is particularly pressing for unresectable PDAC, where inappropriate therapy can lead to significant toxicity without meaningful benefit.

\<Metabolomic Alterations in PDAC> Metabolomics offers a high-throughput and quantitative perspective on tumor phenotype, bridging genotype and clinical outcome. In particular, it presents a novel approach to address this gap by capturing global biochemical changes related to tumor presence, host metabolic response, and cachexia. Once validated, metabolic biomarkers could be translated into rapid and cost-effective assays. Notably, recent studies indicate that metabolite panels can detect PDAC with high accuracy (e.g., plasma metabolic signatures that distinguish PDAC from healthy controls, achieving an AUC of approximately 0.92) and can stratify patients by survival duration. These findings suggest that metabolomic profiling can provide prognostic insights beyond conventional markers.

Regarding treatment response, preliminary metabolomic studies indicate that metabolic profiles can distinguish PDAC patients who respond to chemotherapy from those who exhibit disease progression. Recent plasma metabolomic analyses revealed that patients with progressive diseases during chemotherapy show distinct alterations (e.g., reduced amino acids with FOLFIRINOX and elevated glycolytic and bile acid metabolites with gemcitabine) compared to responders. These profiles suggest a potential stratification tool: participants' pretreatment metabolomic signatures could predict therapy efficacy or resistance. In Aim 1, the investigators will utilize ultra-performance LC-MS/MS to capture a wide range of metabolites in patient sera, aiming to identify metabolic subtypes of unresectable PDAC that correlate with survival or treatment response. This approach builds on emerging evidence that metabolomic profiling can refine PDAC classification and reveal novel therapeutic targets.

\<Immune Profiling and Tumor Microenvironment> PDAC is characterised by a dense desmoplastic stroma and an immunosuppressive tumor microenvironment (TME) that limits the effectiveness of conventional immunotherapy. While checkpoint inhibitors are effective in microsatellite-instability-high PDAC, most PDAC cases are refractory to immunotherapy due to factors such as low tumor immunogenicity and an abundance of suppressive myeloid cells. Recent comprehensive immune profiling has identified at least seven distinct immune subtypes of PDAC tumors, ranging from T cell-rich "inflamed" to immune-desert and various immunosuppressive phenotypes. Interestingly, one-third of patients exhibited a combined myeloid- and metabolite-driven immunosuppressive profile, while a minority (\~3%) had an immune-desert profile devoid of significant lymphocyte infiltration. These findings demonstrate that advanced PDAC is not a uniform entity; substantial immune heterogeneity may impact treatment responses.

Peripheral immune cell populations can partially reflect the TME and thus serve as accessible biomarkers. In PDAC, elevated levels of myeloid-derived suppressor cells and regulatory T cells in circulation correlate with poorer prognosis, whereas higher numbers of effector T cells are associated with better outcomes. In Aim 3, the investigators will perform detailed immune profiling, including flow cytometry of peripheral blood mononuclear cells (PBMCs) to quantify T cell, B cell, NK cell, and myeloid subsets, as well as analysis of tumor tissue (where available) for immune infiltrates and checkpoint molecule expression. By integrating immune data with metabolomic and microbiome findings, the investigators aim to define composite biomarker signatures. The investigators anticipate that linking systemic immune features (e.g., cytokine levels or immune cell ratios) with metabolic and microbial markers will offer a holistic perspective on each patient's disease state. This integrated approach is innovative and may reveal mechanisms-such as metabolite-mediated immune suppression-that underlie therapy resistance

\<Gut Microbiome and PDAC> The gastrointestinal microbiome profoundly influences host metabolism and immunity and is increasingly implicated in pancreatic cancer progression. Bacteria can translocate from the gut to the pancreatic tumor microenvironment, modulating local immune responses and even the metabolism of chemotherapeutic agents. Notably, a high intratumoral microbial diversity has been correlated with prolonged survival in PDAC patients. For example, Riquelme et al. demonstrated that PDAC patients with a more diverse tumor microbiome exhibited significantly improved survival, whereas short-term survivors did not show a dominant microbial profile. Moreover, transplanting stool from long-term survivor PDAC patients into mice altered the tumor immune microenvironment and slowed tumour growth, suggesting a causal role of the gut microbiota in PDAC outcomes. The microbiome also produces metabolites (such as short-chain fatty acids, SCFAs) that can influence cancer biology. For instance, the bacterial metabolite butyrate has been observed to enhance anti-tumor immunity and chemosensitivity in PDAC models. Conversely, dysbiosis may create an immunosuppressive milieu that fosters therapeutic resistance.

In Aim 2, the investigators will profile participants' gut microbiota through 16S rRNA sequencing to identify microbial signatures associated with the metabolic profiles (Aim 1) and clinical outcomes. By correlating microbial diversity and specific taxa with host metabolite patterns, the investigators will explore microbiome-metabolome interactions in PDAC. Identifying gut microbiome correlations with the PDAC phenotype may uncover potentially novel biomarkers (e.g., bacterial taxa or derived metabolites) and therapeutic targets (e.g., microbiota modulation) for advanced disease.

\<Integrative multi-omics and research gap> Each of the domains discussed - metabolism, immune microenvironment, and microbiome - offers a distinct perspective on tumour biology and has demonstrated potential as a source of biomarkers. Importantly, these domains are interconnected; they interact extensively. For instance, tumour metabolic byproducts can influence immune cell function, while gut microbes produce metabolites that circulate and impact both metabolism and immunity. Therefore, an integrative approach may provide deeper insights than any single modality alone. A recent integrative study in PDAC patients supports this idea: Guo et al. combined metabolomic and gut microbiota analyses and found notable differences between resectable and unresectable PDAC cases in both microbial composition and metabolite profiles. They identified key metabolites (such as certain fatty acids and carnitine derivatives) that were significantly altered in advanced disease, some of which correlated strongly with specific gut bacteria. Notably, several of these metabolites and microbes were linked to patient survival - for instance, higher levels of Faecalibacterium (a gut commensal) and certain short-chain fatty acids correlated with longer survival. This study illustrates the feasibility and value of an integrative metabolome-microbiome analysis in PDAC. It also indicates that multi-omics signatures can reflect disease aggressiveness and prognosis.

Despite these insights, significant gaps remain. To date, no study has utilised an integrated approach combining metabolomics, immunology, and microbiome profiling specifically to stratify treatment responses in unresectable pancreatic cancer. Previous research either concentrates on a single domain or investigates broad disease differences (resectable versus advanced) instead of predicting therapy outcomes within an advanced PDAC cohort. Additionally, there is an absence of prospective studies that collect multi-omic data longitudinally alongside treatment, which is vital for creating clinically actionable stratification tools. This study directly addresses this shortcoming by undertaking a comprehensive multi-omic characterisation of unresectable PDAC patients in a prospective manner, with the explicit aim of identifying biomarkers that predict treatment efficacy or failure. By bridging this gap, the investigators intend to facilitate a more personalised approach to treating pancreatic cancer, advancing beyond the current empirical paradigm.

02

Conditions studied

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Keywords

  • Pancreatic ductal adenocarcinoma
  • Metabolomics
  • Microbiome
  • Immune profiling
  • Multi-omic integration
03

In context

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,098 studies on the registry; 241 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will enrol adult patients (age ≥18) with unresectable pancreatic ductal adenocarcinoma, including both locally advanced PDAC (not amenable to surgical resection) and metastatic PDAC. All patients must have histologically or cytologically confirmed pancreatic adenocarcinoma.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Unresectable disease status determined by a multidisciplinary tumour board (either locally advanced disease encasing critical vessels or distant present).
  2. Planned initiation of systemic therapy ( chemotherapy or chemo + experimental immunotherapy trial) as part of standard care - this ensures a uniform starting point for outcome measurement.
  3. Adequate organ function to undergo therapy (renal, hepatic, bone marrow parameters within acceptable range) and an (ECOG) performance status of 0-2, indicating patients well enough to participate and undergo required blood draws and sample collection.
  4. Ability to provide , with no severe comorbid conditions that would preclude study procedures (e.g. unable to provide stool sample or undergo blood draws).

Exclusion criteria

Exclusion Criteria:

  1. Prior systemic therapy for PDAC.
  2. Current use of long-term antibiotics or probiotics that could significantly alter the gut microbiome unless they are willing to pause these interventions (to avoid confounding in microbiome analysis).
  3. Co-existing active that could confound metabolomic or immune readouts, unless it is a low-grade, early cancer in remission.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
140 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Pancreatic Cancer

    Surgically Unresectable Pancreatic Cancer

    Other: Collecting biospecimens

Interventions

  • OtherCollecting biospecimens

    Collecting blood, urine, tissue, and faecal samples

06

What researchers measure

Primary outcomes

  1. Treatment response classification based on metabolomic profiles

    Metabolite signatures will be analyzed for their association with clinical treatment response, defined by radiographic response or disease control. Profiles will be used to classify patients into metabolic phenotypes predictive of therapeutic response.

    Time frame: At baseline (prior to treatment initiation) and at first radiographic evaluation (8-12 weeks after treatment initiation).

Secondary outcomes

  1. Correlation between immune-microbiome landscape and treatment outcomes

    Immune cell phenotyping and 16S rRNA microbiome sequencing will be conducted to identify immunological and microbial profiles associated with clinical response and progression-free survival.

    Time frame: At baseline (prior to treatment initiation); progression-free survival assessed through study completion (up to 18 months).

Other outcomes

  1. Development of a multi-parameter stratification model

    An integrative prediction model combining metabolomic, immune, and microbiome data will be developed and tested for its accuracy in stratifying patients based on expected treatment response and survival.

    Time frame: Model development and internal validation to be completed by study end (up to 30 months after first patient enrollment).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD sharing is not permitted by the local IRB due to ethical and privacy regulations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Jul 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 25, 2025
StartActual
May 28, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2033
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 19, 2026
Sites
Linkou Chang Gung Memorial Hospital is now Recruiting
Nov 19, 2026
Start date
May 1, 2026→May 28, 2026 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Not yet recruiting→Recruiting
    Linkou Chang Gung Memorial Hospital is now Recruiting
    Start date May 1, 2026→May 28, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07036978
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
May 28, 2026
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2033 (estimated)
Last update
Nov 19, 2026

Study contacts

Eric Yi-Liang Shen, MD, PhD
Contact
pts@cgmh.org.tw
886-975366392
Yu-Hsien Chou, MS
Contact
yhc1228@cgmh.org.tw
886-935667922

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion